Natixis Advisors
CRSP icon

Natixis Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Natixis Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,042
Closed -$472K – 1622
2024
Q3 		$472K Sell
10,042
-864
-8% -$43.8K ﹤0.01% 1465
2024
Q2 		$589K Buy
10,906
+400
+4% +$23.1K ﹤0.01% 1397
2024
Q1 		$716K Buy
10,506
+365
+4% +$26.1K ﹤0.01% 1302
2023
Q4 		$634K Sell
10,141
-1,566
-13% -$86.6K ﹤0.01% 1338
2023
Q3 		$531K Sell
11,707
-308
-3% -$15.9K ﹤0.01% 1347
2023
Q2 		$675K Sell
12,015
-434
-3% -$24.6K ﹤0.01% 1262
2023
Q1 		$563K Sell
12,449
-306
-2% -$14.9K ﹤0.01% 1287
2022
Q4 		$519K Sell
12,755
-2,702
-17% -$143K ﹤0.01% 1289
2022
Q3 		$1.01M Sell
15,457
-1,676
-10% -$121K ﹤0.01% 1106
2022
Q2 		$1.04M Sell
17,133
-402
-2% -$23.6K ﹤0.01% 1114
2022
Q1 		$1.1M Buy
17,535
+83
+0.5% +$5.21K ﹤0.01% 1105
2021
Q4 		$1.32M Sell
17,452
-1,676
-9% -$146K 0.01% 1065
2021
Q3 		$2.14M Buy
19,128
+9,104
+91% +$1.14M 0.01% 894
2021
Q2 		$1.62M Buy
+10,024
New +$1.22M 0.01% 981

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Natixis Advisors's CRSP Position: Q4 2024 in Review

Natixis Advisors sold out of CRISPR Therapeutics (CRSP) in Q4 2024, closing a stake of 10,042 shares — an estimated $472K sold.

Natixis Advisors first reported a position in CRSP in Q2 2021 and held it in 14 quarters. The position peaked at $2.14M in Q3 2021. 404 funds tracked by Wall St. Rank hold CRSP as of Q4 2024.

  • Natixis Advisors reported no remaining CRISPR Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Natixis Advisors sold 10,042 CRISPR Therapeutics shares in Q4 2024, an estimated $472K.
  • Natixis Advisors first reported a position in CRISPR Therapeutics in Q2 2021 and held it in 14 quarters.
  • Natixis Advisors's CRISPR Therapeutics position peaked at $2.14M in Q3 2021.
  • 404 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2024.

Based on Natixis Advisors's 13F filing for Q4 2024, filed 10 Feb 2025.